To test if the higher levels of ATF3 and the impaired tumor phenotype upon loss of USP22 in HER2+-BC are caused by sustained activation of the UPR, we analyzed several known markers and genes regulated by this pathway. The gene discussed is ATF3; the disease is breast cancer.